Attagene is a life science company, located in Research Triangle Park, NC, that has been transforming drug development and toxicity testing since 2001.
Attagene has developed and
a first-of-a-kind technology, FACTORIAL™ that enables
high-content assessment of multiple gene regulatory pathways
in live cells. A distinct feature of the FACTORIAL™ platform is that it allows simultaneous assessment of multiple endpoints in a single well of cells,
thereby eliminating intra-assay variations and producing robust and highly reproducible activity profiles.
Using the FACTORIAL™ platform, we constructed a family of assays that enable quantitative assessments of activities of multiple
transcription factors (TFs) and nuclear receptors (NRs) in various cell systems.
The FACTORIAL™ assays have been extensively validated over the years of research contract work for biopharmaceutical companies, academia,
and regulatory agencies. These assays allow for cost-efficient profiling of multiple cell responses to various external stimuli – drugs,
environmental chemicals, natural products, etc., thereby generating wealth of information about biological activities of these substances
that is unattainable with any other technology.
(a.k.a. cis-FACTORIAL™) assay affords profiling activities of over 90 TFs in human and animal cells.
is an embodiment of the TF FACTORIAL™ allowing profiling activities of multiple TFs in the mouse liver.
(a.k.a. trans-FACTORIAL) enables assessing agonist/antagonist activities of compounds against all 48 human NRs.
Having evaluated thousands of various compounds, we discovered robust molecular signatures specifically associated with various biological
activities. ATTAGENE now emerges as a drug discovery company that uses its FACTORIAL™ technology and the vast database of signatures to
identify novel drug candidates with desirable on-target activities and minimal off-target activities among natural compounds and approved drugs.
October 1, 2018 -
publishes a story about Attagene technology.